INTRODUCTION {#sec1_1}
============

Since the near global eradication of poliomyelitis, Guillain-Barré Syndrome (GBS) has become the most common cause of acute neuromuscular paralysis ([@B1]). GBS is an acute neurologic disease driven by autoimmunity and molecular mimicry in which the body stages a cell-mediated and humoral immunological response against peripheral nerve myelin ([@B2]). Asbury and Cornblath clinically defined GBS as a progressive motor weakness of more than one limb with low or absent reflexes and no other identifiable cause ([@B3]). The global incidence of GBS ranges from 0.4 to 4.0 (median 1.3) cases per 100,000 people annually, occurring slightly more often in adolescents and young adults than in children ([@B2], [@B3]). In its acute phase, GBS can cause severe disability and even death ([@B4]). A recent systematic review of GBS estimated that 40--70% of all GBS cases are preceded by an acute infectious illness, of which 22--53% are upper respiratory infections and 6--26% are gastrointestinal infections, one of the most common being enteritis due to *Campylobacter* ([@B5], [@B6]).

GBS can be classified into demyelinating and axonal subtypes. The demyelinating subtype---acute inflammatory demyelinating polyneuropathy (AIDP)---is characterized by demyelination of neurons whereas demyelination is absent in the axonal subtypes---acute motor axonal neuropathy (AMAN) and acute motor sensory axonal neuropathy (AMSAN) ([@B7]). AIDP is common in North America and Europe while AMAN/AMSAN have been more commonly found in studies in China, Japan, and Mexico ([@B2], [@B8], [@B9]). Although both the subtypes have been associated with infection due to *Campylobacter*, it is has been shown that *Campylobacter* is more widely associated with AMAN ([@B10]--[@B12]).

*Campylobacter jejuni* was first associated with GBS in 1982 when Rhodes and Tattersfield reported a case of GBS following enteric infection with *C. jejuni* ([@B13], [@B14]). It is difficult to positively associate *C. jejuni* with GBS because the bacteria are usually eliminated from the body within 16 days of infection and before the onset of neurological symptoms, which normally begin 10 days to 3 weeks after the onset of diarrhoea ([@B1], [@B2]). Although *Campylobacter* is prevalent in most parts of the world, it is not yet routinely diagnosed in rural health clinics. For this reason, many *Campylobacter*-associated GBS cases may go unrecognized because by the time the person presents with GBS, *Campylobacter* is no longer present ([@B15], [@B16]).

Results of a previous overview of literature suggested that *Campylobacter* infection is responsible for 13--72% of GBS cases; however, this review was not designed to systematically review the literature ([@B2]). Thus, we did a systematic review of published studies to estimate the proportion of GBS cases that may be attributed to *Campylobacter* among persons of all ages and from all regions of the world.

MATERIALS AND METHODS {#sec1_2}
=====================

We performed a PubMed search of studies published from July 1982 to 28 June 2010 that investigated the relationship between infection due to *Campylobacter* and GBS. We searched using combinations of the following Medical Subjects Headings (MeSH): 'Guillain-Barré Syndrome' and 'campylobacter' and the key words: 'guillain barré syndrome', 'GBS', 'acute autoimmune neuropathy', 'acute inflammatory polyneuropathy', 'acute inflammatory demyelinating polyneuropathy', 'AIDP', 'AMAN', and 'campylobacter'. We also searched the reference lists of retrieved manuscripts to identify additional studies.

We included cohort studies of persons with laboratory-confirmed infection due to *Campylobacter* who were followed prospectively to assess subsequent GBS cases and retrospective case-control studies that tested for *Campylobacter* infections among GBS-confirmed cases and non-GBS controls. We excluded case-control studies with fewer than 15 GBS cases and cohort studies, including cases of GBS that developed more than six months after a confirmed infection due to *Campylobacter*. Studies were included if serum and stool samples were collected during the acute phase of GBS---within 24--48 hours of patient\'s admission to hospital and no longer than four weeks after admission. Studies were excluded if they relied on a complement fixation assay (CFA) for the diagnosis of *Campylobacter*.

For case-control studies, the primary outcome considered was laboratory-confirmed presence of infection due to *C. jejuni* in GBS cases and controls. For cohort studies, the primary outcome considered was the development of GBS in persons with laboratory-confirmed infection due to *Campylobacter*. Clinical features of GBS were analyzed, and antecedent infections were investigated. Definitions of GBS in the studies were based on currently-accepted criteria for diagnosing GBS (i.e. a progressive, symmetric ascending paralysis with a relative sensory sparing in more than one extremity with hypo- or areflexia) ([@B3], [@B17]). Studies were excluded from review if these did not explicitly state or cite their criteria for diagnosis of GBS. Studies were included if these used appropriate microbiological methods (serological assays and stool cultures) for detecting *Campylobacter* species ([@B13]).

We reviewed all titles and abstracts to identify eligible studies. Full manuscripts were obtained for potentially eligible studies.

Statistical methods {#sec1_2_1}
-------------------

For case-control studies, we calculated the median and interquartile range (IQR) for cases and controls and *Campylobacter*-positive cases and controls. The Microsoft Excel software was used for calculating medians and IQR ([@B18]).

RESULTS {#sec1_3}
=======

We screened 573 potential studies ([Fig.](#F1){ref-type="fig"}) for inclusion in the review. After applying the inclusion and exclusion criteria, we included two prospective cohort studies ([@B16], [@B19]) and 30 case-control studies ([Table](#T1){ref-type="table"}). In total, case-control studies yielded 2,502 GBS subjects and 3,419 controls. One study took place in the UN-classified ([@B20]) least-developed countries ([@B21])---11 in developing countries ([@B10], [@B11], [@B22]--[@B30]) and 20 in developed countries ([@B12], [@B16], [@B19], [@B31]--[@B47]).

![Results of literature review](jhpn0028-0545_f01){#F1}

###### 

Proportions of *Campylobacter* infections in GBS case-control studies

  Author        Year   Country           Duration of study                        GBS cases   Controls                                                                                                                                  
  ------------- ------ ----------------- ---------------------------------------- ----------- ---------------------------------------------- -------------------------------------------------------------------------- --------------- -------------------------
  Islam         2010   Bangladesh        July 2006--June 2007                     97          55 (56.7)[\*](#TF1-001){ref-type="table-fn"}   14/64 AIDP (50.0) 43/64 Axonal[††](#TF1-004){ref-type="table-fn"} (79.1)   97 HOC 97 OND   0 HOC 0 OND
  Kalra         2009   India             2003--2006                               54          15 (27.7)[†](#TF1-002){ref-type="table-fn"}                                                                               42 HC 43 OND    1 (2.3) HC 1 (2.3) OND
  Wierzba       2008   Egypt             Apr 2001--Sep 2003                       133         14 (10.5)[†](#TF1-002){ref-type="table-fn"}    76/120 AIDP 17/120 AMAN                                                    374 HC          26 (7.0)
  Nagashima     2007   Japan             Aug 1999--Feb 2004                       73          23 (31.5)[†](#TF1-002){ref-type="table-fn"}                                                                               73 HC           2 (2.7)
  Sinha         2007   India             Feb 2001--Mar 2005                       80          21 (26.3)[†](#TF1-002){ref-type="table-fn"}    34 AIDP (5.9) 46 Axonal[††](#TF1-004){ref-type="table-fn"} (41.3)          80 HC 45 OND    4 (5.0) HC 2 (4.4) OND
  Gorthi        2006   India             Nov 1997--Aug 1998                       20          7 (35.0)[†](#TF1-002){ref-type="table-fn"}     1 AIDP                                                                     20 HOC 20 OND   5 (25.0) HOC 0 OND
  Schmidt-Ott   2006   Germany           1993--2003                               36          23 (63.9)[†](#TF1-002){ref-type="table-fn"}                                                                               57 NC           2 (3.5)
  Sinha         2004   India             Jun 2001--Mar 2003                       42          2 (4.8)[\*](#TF1-001){ref-type="table-fn"}     18 AIDP (5.6) 24 Axonal[††](#TF1-004){ref-type="table-fn"} (29.2)          42 NC           0
  Liu           2003   China                                                      51          19 (37.3)[†](#TF1-002){ref-type="table-fn"}    20 AIDP (42.1) 28 AMAN (57.9)                                              51 NC           3 (5.9)
  Ho            1999   China             Jan 1992--Dec 1997                       138         99 (71.7)[†](#TF1-002){ref-type="table-fn"}    26 AIDP (50) 72 AMAN (81)                                                  39 NC           6 (15.3)
  Koga          1999   Japan                                                      152         36 (23.7)[†](#TF1-002){ref-type="table-fn"}                                                                               78 OND 69 NC    2 (2.6) OND 6 (8.7) NC
  Yuki          1999   China             Jun 1993--Oct 1995                       55          26 (47.3)[†](#TF1-002){ref-type="table-fn"}    9 AIDP (0) 28 AMAN (53.6)                                                  101 NC          5 (5.0)
  Guarino       1998   Italy             1992--1993                               55          8 (14.5)[†](#TF1-002){ref-type="table-fn"}                                                                                96 HC           3 (3.1)
  Hao           1998   Japan             1990--1996                               205         92 (44.9)[†](#TF1-002){ref-type="table-fn"}                                                                               100 NC          1 (1.0)
  Koga          1998   Japan                                                      201         62 (30.8)[†](#TF1-002){ref-type="table-fn"}                                                                               101 OND 46 NC   8 (8.0) OND 2 (4.3) NC
  Jacobs        1998   Netherlands       Jun 1986--Dec 1989, Sep 1990--Sep 1992   154         49 (31.8)[†](#TF1-002){ref-type="table-fn"}                                                                               154 OND         18 (11.7)
  Saida         1997   Japan             1990--1996                               205         92 (44.9)[†](#TF1-002){ref-type="table-fn"}                                                                               100 NC          1 (1.0)
  Jacobs        1996   Netherlands                                                154         46 (31.8)[†](#TF1-002){ref-type="table-fn"}                                                                               63 OND 50 NC    7 (11.1) OND 4 (8.0) NC
  Ho            1995   China             Jan 1992--Oct 1992                       38          25 (65.8)[†](#TF1-002){ref-type="table-fn"}    12 AIDP (41.7) 21 AMAN (76.2)                                              82 NC           13 (15.9)
  Rees          1995   UK                Nov 1992--April 1994                     96          25 (26.0)[§](#TF1-003){ref-type="table-fn"}                                                                               83 HC 94 HOC    1 (1.2) HC 2 (2.1) HOC
  Tang          1995   China             July 1991--Nov 1993                      16          8 (50)                                                                                                                    90 NC 32 OND    4 (4.4) NC 9 (28.1) OND
  Enders        1993   Germany           1988--1992                               38          15 (39.5)[†](#TF1-002){ref-type="table-fn"}                                                                               39 NC 109 OND   7 (17.9) NC 8 (7.3)
  Gregson       1993   UK                Jan 1987--Feb 1991                       42          15 (35.7)[†](#TF1-002){ref-type="table-fn"}                                                                               41 NC           0
  Yuan          1993   China             Jul 1991--Oct 1992                       17          9 (52.9)[†](#TF1-002){ref-type="table-fn"}                                                                                17 OND 33 NC    3 (17.6) OND 3 (9.1) NC
  Kuroki        1993   Japan             Feb 1985--Jan 1992                       46          14 (30.4)[\*](#TF1-001){ref-type="table-fn"}                                                                              503 NC          6 (1.2)
  Mishu         1993   USA: MD, NJ, MO   1983--1990                               118         43 (36.4)[†](#TF1-002){ref-type="table-fn"}                                                                               103 OND+NC      10 (9.7)
  Vriesendorp   1993   USA               7 years                                  58          10 (17.2)[†](#TF1-002){ref-type="table-fn"}                                                                               42 OND 29 NC    3 (7.1) OND 2 (6.9) NC
  Speed         1987   Australia                                                  45          19 (42.2)[†](#TF1-002){ref-type="table-fn"}                                                                               12 NC           0
  Speed         1984   Australia                                                  27          9 (33.3)[†](#TF1-002){ref-type="table-fn"}                                                                                15 OND          1 (6.7)
  Kaldor        1984   Australia         Jan 1979--Dec 1982                       56          21 (37.5)[†](#TF1-002){ref-type="table-fn"}                                                                               27 OND 30 NC    0 OND 0 NC

\*Stool culture;

†Serological (ELISA),

§Combined results;

AIDP=Acute inflammatory demyelinating polyneuropathy;

††AMAN=Acute motor axonal neuropathy;

\*\*OND=Controls with other neurological disorders (non-GBS);

AMSAN=Acute motor sensory axonal neuropathy;

DC=Controls with other diarrhoea infections;

ELISA=Enzyme-linked immunosorbent assay;

GBS=Guillain-Barré Syndrome;

HC=Hospital controls;

HOC=Household controls;

MD=Maryland;

MO=Missouri;

NC=Normal/healthy controls;

UK=United Kingdom;

US=United States

For case-control studies, rates of *Campylobacter* infection varied among the GBS patients and controls from 4.8% to 71.7% and 0% to 28.1% respectively. The median positivity for *Campylobacter* among the GBS cases was 35.4% (IQR 28.3--44.9), and among the controls, it was 4.4% (IQR 1.2--8.8), suggesting that 31.0% of the GBS cases may be attributable to a previous infection due to *Campylobacter*.

We identified two cohort studies meeting our inclusion criteria ([@B16], [@B19]). In the study by McCarthy *et al.,* 0.03% of *Campylobacter* cases (n=29,563) developed GBS, which can be expressed as 30.4 cases of GBS per 100,000 cases of *C. jejuni*-associated infection \[95% confidence interval (CI) 13.9--57.8\] ([@B16]). In a population-based cohort study, Tam *et al.* found that, of 2,560 persons infected with *Campylobacter* who received subsequent medical follow-up, three cases of GBS were found, yielding an incidence of 117 per 100,000 cases of *C. jejuni* (95% CI 0.38--3.63) ([@B19]).

DISCUSSION {#sec1_4}
==========

In this review, we found 32 studies that met our inclusion/exclusion criteria and measured the association of infection due to *Campylobacter* with GBS. One of the challenges in determining the incidence of *Campylobacter*-associated GBS is that many cases of *Campylobacter* go unreported. For this reason, most studies focus on a sample of persons already diagnosed with GBS and perform retrospective analyses to determine if they were infected with *C. jejuni* ([@B2]). Large cohort studies are ideal for determining the actual incidence of *Campylobacter*-associated GBS because they identify *Campylobacter* cases at the time of active infection and are, thus, less likely to miss a *Campylobacter* infection because of poor timing. Unfortunately, these studies are rare. We used a standard definition for GBS to minimize differences in diagnostic criteria among studies ([@B3]). These are the internationally-accepted criteria currently used for diagnosing GBS and helped control for study heterogeneity.

One limitation of this analysis is controlling for heterogeneity among studies that met our inclusion criteria. Depending on whether studies used serologic assays or stool samples for the diagnosis of *Campylobacter*, different positive values could be shown. Serology is the preferred mechanism of detection because *Campylobacter*-specific antibodies can be detected in serum of the patient for an indefinite length of time compared to *Campylobacter* antigens in stool samples, which are cleared, on average, 16 days after infection. Thus, there could be many false-negative stool cultures in GBS patients in studies that rely solely on stool culture for the diagnosis of *Campylobacter* ([@B48]). Additionally, there is no serological test that is specific for *Campylobacter* infection as far back as in the two months before the onset of GBS; so, there is potential misclassification of exposure in retrospective serological studies, which comprise the bulk of the case-control studies considered in this analysis.

Variations in serological assays could also affect results of study; antigens used and endpoints for positivity often vary with different assays ([@B48]). It is preferable that studies using serology to adhere to strict criteria for recent diagnosis of *Campylobacter* (i.e. positive ELISA for at least 2 classes of antibodies) to avoid false-positive results. However, we did not specifically exclude studies on the basis of the number of *Campylobacter*-specific antibodies they used, only if they did not explicitly state what their standard was for seropositivity of *Campylobacter*. Finally, we did not control for improving technologies for the detection of *Campylobacter* over the years of the studies, which could also confound the comparison of results from older studies with more recent studies.

Another limitation to take into consideration is the overestimation of *Campylobacter* infectivity in control groups. While serological evidence of *Campylobacter* infection is likely indicative of recent infection in GBS cases due to the strong temporal link between *Campylobacter* infection and GBS, this is not the case for controls. If controls test positive, there is no way of knowing how long ago their infection occurred because antibody titres remain elevated for an extended period. The median value of 4.4% for *Campylobacter* positivity in the control group in our study may represent individuals with infection due to *Campylobacter* beyond two months and, thus, could be an overestimate of active *Campylobacter* infections in the general population. If this were the case, the prevalence of *Campylobacter*-associated infections would actually be greater between cases and controls.

The instance of heterogeneous control populations in the studies is an additional limitation of this analysis. Some studies included controls with other neurological disorders with preceding *C. jejuni*-associated infection as high as 28.1%, which is considerably higher than that has been observed in other control groups. Selection of controls in the study could alter the difference in *Campylobacter* positivity between GBS cases and controls, depending on whether the control groups\' risk of exposure was the same as the GBS group or different. For instance, household controls could have a risk comparable to GBS cases, and high rates of seropositivity among these controls could reflect transmission of *Campylobacter* from cases and controls, along with unhygienic living conditions in developing countries.

We were also unable to search the Chinese medical literature databases or review Chinese language papers identified in PubMed. We recognize that these data may exist and would better help us understand the associations of GBS with *Campylobacter* in China.

While infection due to *Campylobacter* is not normally associated with high rates of mortality in developed countries, 4--15% of patients with GBS may die within the first year after onset ([@B49]). *C. jejuni* has been identified as a potential predictor of poor outcome in persons suffering from GBS for inducing a more severe autoimmune response and greater axonal damage ([@B2]). Some studies report that preceding *Campylobacter* infection can increase the severity of GBS in patients, i.e. death, mechanical ventilation, etc. ([@B2]). This is problematic in poorer countries that usually have increased frequencies of infection due to *Campylobacter* because persons who develop GBS may have limited access to healthcare and treatment required for GBS. For these reasons, the appropriate measures must be taken to reduce the incidence of *Campylobacter*-associated GBS. This can be achieved through reducing the frequency of *Campylobacter* cases by improving sanitation, preventing the faecal-oral routes of transmission of *Campylobacter*.
